The Burlo Garofolo Pediatric Institute is a children's hospital located in Trieste, Italy. According to “THE”, Burlo Garofolo is the 1st institute in Italy and the 28th in the world for scientific research quality.

During the past decade, IRCCS Burlo Garofolo conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 1 clinical trials were completed, i.e. on average, 5.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IRCCS Burlo Garofolo" #1 sponsor was "IRCCS Burlo Garofolo" with 12 trials, followed by "Italian Sarcoma Group" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "University of Pisa" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS Burlo Garofolo" #1 collaborator was "Associazione Italiana Ematologia Oncologia Pediatrica" with 2 trials as a collaborator, "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia" with 2 trials as a collaborator, "Centro di Riferimento Oncologico - Aviano" with 1 trials as a collaborator, "Deutsche Krebshilfe e.V., Bonn (Germany)" with 1 trials as a collaborator and "IRCCS Burlo Garofolo" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "IRCCS Burlo Garofolo" are "Juvenile Idiopathic Arthritis" (2 trials), "Pain Relief" (2 trials), "AOSD" (1 trials), "Abdominal Pain" (1 trials) and "Acute Lymphoblastic Leukemia, Pediatric" (1 trials). Many other conditions were trialed in "IRCCS Burlo Garofolo" in a lesser frequency.

Most popular intervention types in "IRCCS Burlo Garofolo" are "Drug" (17 trials), "Other" (5 trials), "Device" (4 trials), "Procedure" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Baricitinib" (3 trials), "Cyclophosphamide" (2 trials), "Doxorubicin" (2 trials), "Etoposide" (2 trials) and "Infliximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS Burlo Garofolo" are 28 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "IRCCS Burlo Garofolo". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in IRCCS Burlo Garofolo, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS Burlo Garofolo, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".

IRCCS Burlo Garofolo has several departments that took part in Clinical trials: "Emergency Department, IRCCS Burlo Garofolo" - 2 trials, "U.O. Emato-Oncologia Pediatrica Università degli studi di Trieste Ospedale Infantile Burlo Garofolo" - 2 trials